COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS AFLIBERCEPT IN TREATMENT OF TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR OEDEMA (DMO)

被引：0
|
作者：
Haig, J. [1 ]
Regnier, S. A. [2 ]
Malcom, W. [3 ]
Xue, W. [4 ]
机构：
[1] Optum, Burlington, ON, Canada
[2] Novartis AG, Basel, Switzerland
[3] Novartis UK LTD, Frimley Camberley, Surrey, England
[4] Optum, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2132
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS34
引用
收藏
页码：A609 / A609
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective
    Regnier, Stephane A.
    Malcolm, William
    Haig, Jennifer
    Xue, Weiguang
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 235 - 247
  • [2] Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema
    Haig, Jennifer
    Barbeau, Martin
    Ferreira, Alberto
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 663 - 671
  • [3] COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS LASER PHOTOCOAGULATION AND RANIBIZUMAB IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA IN CHINA
    Ming, J.
    Zhang, Y.
    Xu, X.
    Zhao, M.
    Wang, Y.
    Chen, Y.
    Zhang, F.
    Wang, J.
    Liu, J.
    Zhao, X.
    Han, R.
    Hu, S.
    VALUE IN HEALTH, 2019, 22 : S580 - S580
  • [4] RANIBIZUMAB FOR THE TREATMENT OF VISUAL IMPAIRMENT DUE TO MYOPIC CHOROIDAL NEOVASCULARIZATION: COST-EFFECTIVENESS VERSUS AFLIBERCEPT
    Leteneux, C.
    Haig, J.
    Xue, W.
    Bhattacharyya, S.
    VALUE IN HEALTH, 2014, 17 (07) : A608 - A608
  • [5] COST-EFFECTIVENESS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA IN SPAIN
    Granell Villalon, M.
    Riera, M.
    Boixadera, A.
    Villacampa, A.
    Mondejar, J.
    Deschaseaux, C.
    VALUE IN HEALTH, 2018, 21 : S428 - S428
  • [6] COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS LASER IN THE TREATMENT OF VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR OEDEMA (DME) FROM THE COLOMBIAN HEALTH CARE SYSTEM PERSPECTIVE
    Karpf Benavides, E.
    Escobar, L. M.
    Naranjo, J.
    VALUE IN HEALTH, 2014, 17 (03) : A286 - A286
  • [7] Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
    Christian Bührer
    Thomas Paling
    Richard Gale
    Tatiana Paulo
    Marloes Bagijn
    PharmacoEconomics - Open, 2024, 8 : 445 - 457
  • [8] Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
    Buhrer, Christian
    Paling, Thomas
    Gale, Richard
    Paulo, Tatiana
    Bagijn, Marloes
    PHARMACOECONOMICS-OPEN, 2024, 8 (03) : 445 - 457
  • [9] Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial
    Mitchell, Paul
    Annemans, Lieven
    Gallagher, Meghan
    Hasan, Rafiq
    Thomas, Simu
    Gairy, Kerry
    Knudsen, Martin
    Onwordi, Henrietta
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2012, 96 (05) : 688 - 693
  • [10] Summary of Research: Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
    Buehrer, Christian
    Paling, Thomas
    Gale, Richard
    Paulo, Tatiana
    Bagijn, Marloes
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (08) : 2063 - 2066
12345